<unk>  (LU-135252; HMR-4005) is an endothelin receptor antagonist. Gilead Colorado, a subsidiary of Gilead Sciences, under license from Abbott Laboratories, is developing<unk>  for the potential treatment of uncontrolled hypertension. In June 2003, Myogen licensed the compound from Abbott for its application in the cancer field. In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints.
Darusentan
Bosentan
Sitaxentan
Macitentan
Ambrisentan
Vericiguat
Sildenafil
Minoxidil